Estimation of Free Phenytoin Concentration in Critically Ill Patients with Hypoalbuminemia: Direct-measurement Vs Traditional Equations

Overview

Journal Indian J Crit Care Med

Specialty Critical Care

Date 2022 Jul 15

PMID 35836626

Authors

Premila M Wilfred

Sumith Mathew

Binila Chacko

Ratna Prabha

Binu Susan Mathew

Affiliations

Soon will be listed here.

Abstract

Background: In critically ill patients with low albumin, dose individualization of phenytoin is a challenge. The currently used Sheiner-Tozer equation does not accurately predict the free phenytoin concentration in serum and can result in incorrect dose modifications. The best measure to advocate in these patients is the direct-measurement of free phenytoin concentration.

Aims And Objectives: Phenytoin exhibits complex pharmacokinetics, requiring careful therapeutic drug monitoring. This study aimed to compare the accuracy of the established Sheiner-Tozer calculation method against the direct-measurement of free phenytoin concentration in serum by high performance liquid chromatography in critically ill patients with low albumin.

Materials And Methods: Blood specimens for direct-measurement of both total and free phenytoin concentration were obtained from 57 patients with hypoalbuminemia monitored in the intensive care unit.

Results: The median [inter-quartile range (IQR)] for Sheiner-Tozer equation calculated total phenytoin concentration and direct-measured total was 17.14 (10.63-24.53) and 9.82 (6.02-13.85) μg mL, respectively. Approximately 53 and 5% of patients were found to be subtherapeutic and supratherapeutic for direct-measured total phenytoin concentrations, respectively. In contrast, on applying the Sheiner-Tozer calculation, 23 and 40% had subtherapeutic and supratherapeutic concentrations, respectively, for total phenytoin concentration. The median (IQR) for direct-measured, routine and Sheiner-Tozer equation calculated free phenytoin concentration were 1.92 (1.06-2.76), 0.98 (0.60-1.39), and 1.71 (1.06-2.45) μg mL, respectively. Only 45.7% of patients were in agreement with respect to the therapeutic category when direct-measured free was compared against routine calculation free.

Conclusion: In patients with low albumin, free phenytoin concentration based on the Sheiner-Tozer corrected equation accurately classified patients based on their therapeutic category of free phenytoin in 73.7% of patients. Hence, for individualization of phenytoin dosage in critically ill patients with low albumin, we recommend direct-measurement of free phenytoin concentration.

How To Cite This Article: Wilfred PM, Mathew S, Chacko B, Prabha R, Mathew BS. Estimation of Free Phenytoin Concentration in Critically Ill Patients with Hypoalbuminemia: Direct-measurement vs Traditional Equations. Indian J Crit Care Med 2022;26(6):682-687.

References

Munoz-Pichuante D, Villa Zapata L, Cabrera S, Lagos X, Grandjean J . Dosage of phenytoin in neurocritical patients using Bayesian algorithms: a pilot study. Drug Metab Pers Ther. 2020; 34(4). DOI: 10.1515/dmpt-2019-0015. View

Peterson G, McLean S, Aldous S, von Witt R, MILLINGEN K . Plasma protein binding of phenytoin in 100 epileptic patients. Br J Clin Pharmacol. 1982; 14(2):298-300. PMC: 1427743. DOI: 10.1111/j.1365-2125.1982.tb01981.x. View

Thakkar A, Bendkhale S, Taur S, Gogtay N, Thatte U . Association of CYP2C9 polymorphisms with phenytoin toxicity in Indian patients. Neurol India. 2013; 60(6):577-80. DOI: 10.4103/0028-3886.105189. View

Masapu D, Gopala Krishna K, Sanjib S, Chakrabarti D, Mundlamuri R, Manohar N . A Comparative Study of Midazolam and Target-Controlled Propofol Infusion in the Treatment of Refractory Status Epilepticus. Indian J Crit Care Med. 2018; 22(6):441-448. PMC: 6020637. DOI: 10.4103/ijccm.IJCCM_327_17. View

Tobler A, Hosli R, Muhlebach S, Huber A . Free phenytoin assessment in patients: measured versus calculated blood serum levels. Int J Clin Pharm. 2016; 38(2):303-9. DOI: 10.1007/s11096-015-0241-x. View

Tacker D, Robinson R, Perrotta P . Abbott ARCHITECT iPhenytoin assay versus similar assays for measuring free phenytoin concentrations. Lab Med. 2014; 45(2):176-81. DOI: 10.1309/lm28b9dsrjcbcwwj. View

Patsalos P, Berry D, Bourgeois B, Cloyd J, Glauser T, Johannessen S . Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008; 49(7):1239-76. DOI: 10.1111/j.1528-1167.2008.01561.x. View

Doucet J, Fresel J, Hue G, Moore N . Protein binding of digitoxin, valproate and phenytoin in sera from diabetics. Eur J Clin Pharmacol. 1993; 45(6):577-9. DOI: 10.1007/BF00315318. View

Giancarlo G, Venkatakrishnan K, Granda B, von Moltke L, Greenblatt D . Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur J Clin Pharmacol. 2001; 57(1):31-6. DOI: 10.1007/s002280100268. View

10.

Nicholson J, Wolmarans M, Park G . The role of albumin in critical illness. Br J Anaesth. 2000; 85(4):599-610. DOI: 10.1093/bja/85.4.599. View

11.

Jain S, Gautam V, Naseem S . Acute-phase proteins: As diagnostic tool. J Pharm Bioallied Sci. 2011; 3(1):118-27. PMC: 3053509. DOI: 10.4103/0975-7406.76489. View

12.

Hong J, Choi Y, Kim W . Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients. Yonsei Med J. 2009; 50(4):517-20. PMC: 2730613. DOI: 10.3349/ymj.2009.50.4.517. View

13.

Zafar S, Khan A, Ghauri A, Shamim M . Phenytoin versus Leviteracetam for seizure prophylaxis after brain injury - a meta analysis. BMC Neurol. 2012; 12:30. PMC: 3406949. DOI: 10.1186/1471-2377-12-30. View

14.

Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Okuda M . Clinical evaluation of plasma free phenytoin measurement and factors influencing its protein binding. Biopharm Drug Dispos. 2005; 27(2):77-84. DOI: 10.1002/bdd.486. View

15.

Montgomery M, Chou J, McPharlin T, Baird G, Anderson G . Predicting Unbound Phenytoin Concentrations: Effects of Albumin Concentration and Kidney Dysfunction. Pharmacotherapy. 2019; 39(7):756-766. DOI: 10.1002/phar.2273. View

16.

Imam S, Landry K, Kaul V, Gambhir H, John D, Kloss B . Free phenytoin toxicity. Am J Emerg Med. 2014; 32(10):1301.e3-4. DOI: 10.1016/j.ajem.2014.03.036. View

17.

Parikh L, MacLaren R . The predictive performances of equations used to estimate unbound phenytoin concentrations in a medical ICU population and the impact of exogenous albumin administration. J Crit Care. 2017; 44:95-100. DOI: 10.1016/j.jcrc.2017.10.028. View

18.

Kilpatrick C, Wanwimolruk S, Wing L . Plasma concentrations of unbound phenytoin in the management of epilepsy. Br J Clin Pharmacol. 1984; 17(5):539-46. PMC: 1463454. DOI: 10.1111/j.1365-2125.1984.tb02387.x. View

19.

Barra M, Phillips K, Chung D, Rosenthal E . A Novel Correction Equation Avoids High-Magnitude Errors in Interpreting Therapeutic Drug Monitoring of Phenytoin Among Critically Ill Patients. Ther Drug Monit. 2020; 42(4):617-625. PMC: 7377971. DOI: 10.1097/FTD.0000000000000739. View

20.

Dasgupta A . Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta. 2006; 377(1-2):1-13. DOI: 10.1016/j.cca.2006.08.026. View